| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/09/2001 | WO2001056552A2 Farnesyl protein transferase inhibitors for treating breast cancer |
| 08/09/2001 | WO2001056549A1 Continuous method for preparing pharmaceutical granules |
| 08/09/2001 | WO2001056547A2 Preparation of aqueous clear solution dosage forms with bile acids |
| 08/09/2001 | WO2001056532A2 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001007027A3 Pyrimidine derivatives for the treatment of viral diseases |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001003687A3 Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans |
| 08/09/2001 | WO2000076487A3 Use of paclitaxel and steriod derivatives as aromatase inhibitors for the treatment of cancer |
| 08/09/2001 | WO2000074729A3 Alpha or beta emitters to fragments in radioimmunotherapy |
| 08/09/2001 | WO2000066173A3 Targeting of infectious agents bearing host cell proteins |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000063351A3 Carbohydrate-modifying enzymes |
| 08/09/2001 | WO2000062813A3 Cationic peg-lipids and methods of use |
| 08/09/2001 | WO2000057862A3 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 08/09/2001 | US20010012885 Conjugate consisting of an active substance and a non-exogeneous native protein |
| 08/09/2001 | US20010012858 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 08/09/2001 | US20010012856 Compositions and methods for the treatment of anorectal disorders |
| 08/09/2001 | US20010012853 Methods for regulating skin appearance |
| 08/09/2001 | US20010012851 A carbamate, carbonate or carboxasulfide containing oxindole compound used for treating osteroarthritis, an inflammatory disease or degenerative joint disease without causing side effect |
| 08/09/2001 | US20010012849 Pharmaceutical composition and method for treatment of inflammation |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | US20010012838 Methods for inhibiting bone resorption |
| 08/09/2001 | US20010012836 Determining the presence or absence of a mutation in the nucleotide sequence or absence of a mutation in nucleotide sequence encoding the specific polypeptides in the genome of the subject and analyzing for presence of polypeptide |
| 08/09/2001 | US20010012834 Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| 08/09/2001 | US20010012627 Neurotransmitter transporter SC6 |
| 08/09/2001 | US20010012621 Determining the expression of lysyl oxidase, the expression of lysyl oxidase indicating that the compound is capable of suppressing ras functions |
| 08/09/2001 | US20010012515 Isolated polypeptide |
| 08/09/2001 | DE19953517C1 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation Use of treosulphan for conditioning of patients before Knochemarktransplantation or blood stem cell transplantation |
| 08/09/2001 | CA2762121A1 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome |
| 08/09/2001 | CA2400013A1 Methods of protein destabilization and uses thereof |
| 08/09/2001 | CA2399982A1 G-protein coupled receptors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399672A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399267A1 Protein c derivatives |
| 08/09/2001 | CA2399058A1 Targeting peptides |
| 08/09/2001 | CA2399034A1 Continuous method for preparing pharmaceutical granules |
| 08/09/2001 | CA2398889A1 Antisense modulation of survivin expression |
| 08/09/2001 | CA2398261A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | CA2398250A1 Interaction of nmda receptor with protein tyrosine phosphatase |
| 08/09/2001 | CA2396774A1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 08/08/2001 | EP1122318A2 Diagnostic method for the detection of polymorphisms related to the human urokinase plasminogen activator receptor |
| 08/08/2001 | EP1121939A2 Treatment of osteoporosis with EP2/EP4 receptor selective agonists |
| 08/08/2001 | EP1121464A1 Polymorphism in a tgf-ss gene correlated to osteoporosis |
| 08/08/2001 | EP1121456A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 08/08/2001 | EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121439A2 Methods and compositions for inhibiting neoplastic cell growth |
| 08/08/2001 | EP1121433A2 Human ankyrin family protein |
| 08/08/2001 | EP1121432A2 G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 08/08/2001 | EP1121431A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121427A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 08/08/2001 | EP1121363A2 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 08/08/2001 | EP1121354A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3? agonists or antagonists |
| 08/08/2001 | EP1121157A1 A novel component in the hedgehog signalling pathway |
| 08/08/2001 | EP1121150A1 Delta 6 fatty acid desaturase |
| 08/08/2001 | EP1121140A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 08/08/2001 | EP1121133A1 Methods for stimulating bone formation |
| 08/08/2001 | EP1121132A1 Method and compositions for increasing bone mass |
| 08/08/2001 | EP1121131A2 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 08/08/2001 | EP1121129A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 08/08/2001 | EP1121128A1 A method of modulating ion channel functional activity |
| 08/08/2001 | EP1121113A1 Methods for regulating bone formation |
| 08/08/2001 | EP1121112A2 Storable active substance concentrate with formoterol |
| 08/08/2001 | EP1121111A2 Compounds for the treatment of weight loss |
| 08/08/2001 | EP1121109A2 Opioid analgesic |
| 08/08/2001 | EP1121108A2 Novel therapeutic use of compounds with beta-3-agonist activity |
| 08/08/2001 | EP1121106A1 Treatment of dyspepsia |
| 08/08/2001 | EP1121102A1 Liposome-entrapped topoisomerase inhibitors |
| 08/08/2001 | EP1121101A1 Aerosol ointment compositions and method of manufacture |
| 08/08/2001 | EP1024792A4 Topical antifungal composition |
| 08/08/2001 | EP0960118A4 Nucleotide and protein sequences of liver activin/inhibin and methods based thereon |
| 08/08/2001 | EP0824357B1 The use of epidermal growth factor as a gastrointestinal therapeutic agent |
| 08/08/2001 | EP0815133A4 Human stat4 |
| 08/08/2001 | CN1307590A Treating and diagnosing macrophage-mediated diseases using FC receptor ligands |
| 08/08/2001 | CN1307471A Use of NMDA antagonists for treatment of irritable bowel syndrome |
| 08/07/2001 | US6271615 Brush holder |
| 08/07/2001 | US6271390 Suppression of the IgE-dependent allergic response by benzimidazole analogs |
| 08/07/2001 | US6271268 Treatment of gland disorders with antisecretory agents such as acyl coa cholesterol acyl transferase(acat) inhibitors or prodrugs |
| 08/07/2001 | US6271246 Antidandruff composition with acidic component having alpha-or beta-hydroxy acid or tannic acid which exfoliates scalp; vitamin a component inhibits overproducing stratum corneum; antigrowth agent inhibits fungus, yeast, and bacteria |
| 08/07/2001 | US6271245 Hydroxamic acid derivatives |
| 08/07/2001 | US6271244 N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
| 08/07/2001 | US6271243 Pharmaceutical composition |
| 08/07/2001 | US6271228 Blood pressure stabilization during hemodialysis |
| 08/07/2001 | US6271217 Method of treating cancer with a benzimidazole and a chemotherapeutic agent |
| 08/07/2001 | US6271213 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| 08/07/2001 | US6271204 Activation of pyruvate dehydrogenase phosphatase |
| 08/07/2001 | US6271200 Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 08/07/2001 | US6271199 Treatment of infarcts |
| 08/07/2001 | US6270994 Smad6 and uses thereof |
| 08/07/2001 | US6270992 Histidine kinase of Staphylococcus aureus |
| 08/07/2001 | US6270747 Inhibiting hypersecretion of mucus in lungs and airways by the administration of an egf-r antagonist. |
| 08/07/2001 | CA2025607C Hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents |
| 08/02/2001 | WO2001055725A2 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 08/02/2001 | WO2001055692A2 Neurosteroids as markers for alzheimer's disease |